top of page

Next‑Generation Antimicrobials Built to Scale

We develop scalable, affordable bacteriophage-based therapeutics for real-world infectious disease burdens, with Africa as the foundation for global scale.

The AMR Crisis

Antimicrobial resistance (AMR) is a global crisis that is accelerating across Africa, driven by high infectious disease burden, limited diagnostics, and over‑reliance on failing antibiotics. Many therapies developed for high‑income markets do not translate effectively to African pathogen ecology.

 

Kaserta Therapeutics is at the forefront of battling AMR infections through cutting-edge bacteriophage treatments. Our goal is to provide quicker, more affordable healthcare solutions by focusing on neglected but socially crippling infections in the African market.

Why Phages?

In a world facing increasing antibiotic resistance, we utilize innovative biologic therapies to address unmet health needs. With our adaptable technology, we are poised to navigate the evolving regulatory landscape while maintaining a strong focus on patient outcomes.

Why Africa?

Kaserta advances product innovation alongside new business models designed to expand access and impact. We believe Africa presents the most compelling ground zero for out project, and if we succeed in Africa, we can succeed anywhere. 

Innovation

Our Approach

Our technology employs bacteriophages, viruses that specifically target and destroy bacteria, providing an effective alternative to conventional antibiotics. This targeted approach minimizes side effects and enhances the healing process.

By focusing on hard-to-treat infections, our research and development pave the way for safer treatments that adapt to regulatory changes and market demands, ensuring patients receive timely and effective care.

Our Team.

Our team combines bacteriophage science, AI-driven data platforms, clinical infectious disease expertise, and institutional execution. This integrated approach allows us to build a durable platform that supports the systematic development of a robust and evolving portfolio of phage-based products for global markets.

bottom of page